Peter Radovich Sells 16,515 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 16,515 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $1,519,049.70. Following the transaction, the chief operating officer directly owned 40,272 shares in the company, valued at approximately $3,704,218.56. The trade was a 29.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Peter Radovich also recently made the following trade(s):

• On Monday, February 2nd, Peter Radovich sold 2,631 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $103.30, for a total transaction of $271,782.30.
• On Monday, January 26th, Peter Radovich sold 3,143 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $96.19, for a total transaction of $302,325.17.
• On Thursday, January 22nd, Peter Radovich sold 2,382 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.33, for a total transaction of $222,312.06.

Mirum Pharmaceuticals Trading Down 5.1%

MIRM stock opened at $91.66 on Thursday. The company has a current ratio of 2.67, a quick ratio of 2.55 and a debt-to-equity ratio of 0.98. Mirum Pharmaceuticals, Inc. has a 12-month low of $36.88 and a 12-month high of $109.28. The stock has a market cap of $5.53 billion, a price-to-earnings ratio of -190.95 and a beta of 0.52. The business’s 50-day moving average is $96.32 and its 200 day moving average is $81.08.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). The firm had revenue of $148.93 million for the quarter, compared to analyst estimates of $141.78 million. Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. Mirum Pharmaceuticals’s revenue was up 49.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.00 EPS. On average, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum announced completion of enrollment in the Phase 3 EXPAND study of LIVMARLI (maralixibat) for additional rare cholestatic liver diseases — a material clinical milestone that keeps the program on track; topline readout is expected in Q4 2026 and could materially re‑rate the stock if positive. Mirum EXPAND Enrollment Milestone Highlights LIVMARLI Upside And Valuation Gap
• Neutral Sentiment: Institutional investors and analysts show continued interest: several large institutions increased positions in recent quarters and multiple sell‑side firms have raised price targets (consensus remains a “Moderate Buy” with a mid‑teens upside to consensus targets). This supports underlying demand but is not an immediate catalyst. MarketBeat Mirum Stock Page
• Negative Sentiment: Several insiders sold sizable blocks of stock on March 16 (CEO Christopher Peetz sold 40,985 shares for ~$3.77M; COO Peter Radovich sold 16,515 shares; CFO Eric Bjerkholt, SVP Jolanda Howe and others also sold) — all at an average price near $91.98. Large, clustered insider sales can be interpreted as profit‑taking and often weigh on sentiment even when executives retain meaningful stakes. SEC filing for the CEO sale: Peetz Form 4 — SVP sale coverage: InsiderTrades SVP Sale

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on MIRM shares. Raymond James Financial reaffirmed a “strong-buy” rating and set a $110.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Stifel Nicolaus raised their price target on shares of Mirum Pharmaceuticals from $98.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Citizens Jmp lowered their price target on shares of Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating on the stock in a research report on Thursday, February 26th. Wall Street Zen cut shares of Mirum Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $117.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Cullen Frost Bankers Inc. acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in Mirum Pharmaceuticals during the fourth quarter worth about $32,000. CIBC Private Wealth Group LLC acquired a new stake in Mirum Pharmaceuticals during the fourth quarter worth about $32,000. MCF Advisors LLC raised its stake in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares during the period. Finally, Quantbot Technologies LP acquired a new position in Mirum Pharmaceuticals in the 3rd quarter valued at about $33,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.